undamentalytics Newsletter
Sign in

Castle Biosciences Inc balance sheet

At the end of fiscal 2025, Castle Biosciences Inc had total assets of $579m, total liabilities of $108m and shareholders' equity of $471m. It held $117m in cash against $10.2m of debt: net cash of $107m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents4994103301239912011762
Receivables121513172338514348
Inventory11224881011
Total current assets18117430354292296360361341
Goodwill———01111111111
Total assets22120439463447453531579561
Accounts payable122351071910
Deferred revenue (current)—070—————
Total current liabilities71521253648496957
Short-term debt060——0003
Long-term debt25190——010107
Total debt25270000101010
Total liabilities3235245148627510891
Shareholders' equity−5785416412399391456471470
Non-controlling interests and other (assets − liabilities − equity)46————————
Net debt (negative = net cash)20−72−410−330−123−99−110−107−52
Shares outstanding2m——25m27m27m28m30m31m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CSTL vs FLGTCSTL vs TWSTCSTL vs SDGR

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Castle Biosciences Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Castle Biosciences Inc.